Evidence-based reviews have assumed important roles in clinical medicine. They offer the clinician comprehensive and timely status reports of what is known about current treatment approaches for a given disease and how well the data support what we think we know. Perhaps equally important is what a review reveals about what we do not know, especially if it challenges some presumptions about what we think we know that are not firmly established. Identification of gaps in knowledge and delineation of research priorities is another important function of the evidence-based review.
INTRODUCTION

Introduction
The American Society for Blood and Marrow Transplantation (ASBMT) in 1999 began an initiative to sponsor evidence-based reviews of the scientific and medical literature for the use of blood and marrow transplantation in the therapy of selected diseases. The first review in the series evaluating published reports on diffuse large cell B-cell nonHodgkin' s lymphoma was published in 2001 [1] . The following is an edited and abridged version of the second review in which an expert panel assembled and critically evaluated all of the evidence regarding the role of cytotoxic therapy with hematopoietic stem cell transplantation (SCT) in the therapy of multiple myeloma (MM), made treatment recommendations based on the available evidence, and identified needed areas of research [2] . Additional sections that are included in the full-length version of the review but are not presented here include: therapy post-SCT, SCT economic/cost-effectiveness studies, response criteria (methods to detect minimum residual disease), ongoing studies, limitations of this review, and future initiatives.
The published literature was graded in a systematic manner on the quality of design (Table 1 ) and the strength of the evidence (Table 2 ). Treatment recommendations subsequently were graded based on the quality and strength of the evidence (Table 3) .
Literature Search Methodology
PubMed was systematically searched using the MeSH terms "multiple myeloma" and "transplant." Specific inclusion and exclusion criteria are detailed in the unabridged version of the review.
Qualitative and Quantitative Grading of the Evidence
The hierarchy of evidence, including a grading scheme for the quality and strength of the evidence and strength of each treatment recommendation, was established and published as an editorial policy statement in Biology of Blood and Marrow Transplantation [3] . Study design, including sample size, patient selection criteria, duration of followup, and treatment plan, also was considered in evaluating the studies.
In this review, stem cell transplantation (SCT) is used as a general term that includes bone marrow transplantation (BMT) and/or peripheral blood stem cell transplantation (PBSCT). De novo therapy refers to only one chemotherapy regimen given before stem cell mobilization and transplantation, and salvage therapy refers to 2 or more chemotherapy regimens given before stem cell mobilization and transplantation. DS indicates DurieSalmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; PFS, progression-free survival; FFP, freedom from progression; chemo, standard chemotherapy comparison group; NYR, not yet reached; NS, not stated in article; NC, no comparison given in article.
The treatment recommendations of the expert panel are detailed in Table 4 . Table 5 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles, some of which are detailed in this section. Table 1 . Grading the Quality of the Evidence* 1 Evidence obtained from at least one properly randomized controlled trial 2-1 Evidence obtained from well-designated, controlled trials without randomization 2-2 Evidence obtained from well-designated, cohort or case-controlled analytic studies, preferably from more than one center or research group 2-3 Evidence obtained from multiple timed series with or without the intervention, or from dramatic results in uncontrolled experiments 3 Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees 4 Evidence inadequate owing to problems of methodology, eg, sample size, length or comprehensiveness of follow-up, or conflict in evidence ) and total body irradiation (TBI). Recombinant interferon α (IFNa) was administered in 73% of patients in the chemotherapy group starting at cycle 9 until occurrence of relapse (total duration a median of 12 months), and in 70% of the patients in the BMT group starting after hematologic reconstitution (median total duration 11 months). Patients were randomly assigned to 1 treatment arm; 74% of the patients in the BMT group underwent transplantation.
Transplantation versus Chemotherapy
By intent-to-treat, patients in the BMT group had a significantly higher response rate of 38% versus 14% in the chemotherapy group (P < .001). At a median follow-up measured from the time of randomization of 37 months in the chemotherapy group and 41 months in the BMT group, the BMT group had significantly longer event-free survival (EFS) (P = .01) and overall survival (OS) (P = .03) (Figure 1 ).
Barlogie et al. performed a phase II study of a planned tandem transplantation regimen as part of "total therapy" consisting of vincristine, adriamycin, and dexamethasone (VAD) for 3 cycles, followed by high-dose cyclophosphamide (Cy) and granulocytemacrophage colony-stimulating factor (GM-CSF); peripheral blood stem cell (PBSC) and/or BM collection; and 1 cycle of etoposide, dexamethasone, cytosine arabinoside, and cisplatinum (EDAP) [5] .
For comparison, a sample of historical patients enrolled in Southwest Oncology Group (SWOG) trials 8229 (alternating versus syncopated regimen of VMCP/BVAP) and 8624 (VMCP/BVAP versus VMCPP/BVAPP versus VAD) were pair-matched to the tandem transplantation patients based on age, β-2 microglobulin (B2M), and serum creatinine levels. By intent-to-treat, patients enrolled in the tandem transplantation trial had a significantly higher response rate (≥partial response [PR] ) than the pair-matched SWOG trial patients (86% versus 52%; P = .0001), longer median duration of EFS (49 versus 22 months; P = .0001), and longer median duration of OS (62+ versus 48 months; P = .01) (Figure 2 ).
Lenhoff et al. compared 348 symptomatic, newly diagnosed, previously untreated MM patients aged younger than 60 years treated with high-dose therapy from a prospective population-based study (274 of whom were treated according to a Nordic Myeloma Study Group protocol NMSG #5/94) with 313 his- *SCT indicates stem cell transplantation; PBSCT, peripheral blood SCT; BMT, bone marrow transplantation; TBI, total body irradiation; IFNa, interferon α.
†Definitions: See Table 3 . ‡Definitions: See Table 1 . §The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in the review. [7] . Patients who underwent PBSCT were compared with a sample of 71 patients (treated 1990 to 1995) matched by age and B2M chosen from a cohort of symptomatic MM patients treated at diagnosis with oral melphalan-prednisolone and who met eligibility criteria for the PBSCT regimen. By intent-to-treat, OS and EFS were significantly longer for the PBSCT group. 
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Alexanian et al. compared 68 MM patients who received autologous BMT or PBSCT within 1 year after the start of induction chemotherapy with responsive disease (PR or complete response [CR] to induction) with 50 concurrent control patients with similar disease characteristics and prognostic factors who met the eligibility criteria for intensive therapy but did not receive a transplant [8, 9] . Median OS of patients who converted from PR to CR after SCT was significantly longer (8.3 years) than those who remained in PR after SCT (5.0 years) and the controls with persistent PR after standard therapy (4.4 years) (P = .03).
Salvage
Alexanian et al. studied 49 MM patients who received VAD plus autologous BMT or PBSCT compared with 79 contemporaneous controls who received VAD but did not meet the eligibility criteria for myeloablative therapy [11] . There was no significant difference between the VAD plus transplantation versus the VAD patients with respect to OS or disease-free survival (DFS).
Mixed Disease Stage (De Novo and Salvage)
Malpas et al. retrospectively compared a cohort of 156 patients treated with conventional chemotherapy (n=120) or autologous BMT (n=36) [12] . OS in the BMT group was prolonged (median 6 years) compared to the conventional chemotherapy group (median 20 months). Multivariate analysis showed increasing age (P = .05) and treatment with conventional chemotherapy (P = .002) were independent risk factors for shorter OS.
Gertz et al. also reported on 118 MM patients who had VAD ×4 cycles as either induction or re-induction (after prior MELbased chemotherapy) therapy) [13] . A total of 67 patients underwent PBSCT (11 early treatment failures and 56 as a result of progression on or off maintenance therapy) with a median OS after PBSCT of 17.2 months. Median OS from initial MM diagnosis of all 118 transplantation and non-transplantation patients was 58.5 months. There was no comparison of PBSCT as de novo versus salvage therapy. Table 6 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles, some of which are detailed in this section.
Timing of Transplantation (De Novo versus Salvage)
Fermand et al. performed a multicenter prospective randomized trial comparing the optimal timing of autologous PBSCT [14] . At a median follow-up of 58 months, there was no significant difference in OS, however, there was a significant difference in EFS; the early transplantation group' s median was 39 months versus the late transplantation group' s median of 13 months. The median time without symptoms, treatment, or treatment toxicity (TWiSTT) was 27.8 months for the early transplantation group and 22. 
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Blood and Marrow TRANSPLANTATION divided into 2 groups for analysis: 44 salvage and 53 de novo patients. Those treated as de novo had a longer median OS from a first course of high-dose MEL compared with those given high-dose MEL plus SCT as salvage therapy (37 versus 17 months; P = .16). In the 35 patients who received autologous SCT, there was no significant difference in OS or progression-free survival (PFS).
Alegre et al. reported on 259 MM patients from the Spanish Registry (GETH and PETHEMA) treated with autologous PBSCT [17] . Multivariate analysis showed the only independent factors associated with OS and PFS were number of chemotherapy regimens (1 versus other) prior to autologous PBSCT and the disease status prior to PBSCT (CR/PR versus other). 2 ) for 2 cycles (n = 62) or IDM for 2 cycles (n = 15) as induction therapy [18] . Patients with at least a PR to induction therapy and an adequate stem cell harvest and who were aged younger than 65 years received autologous PBSCT followed by IFNa maintenance (n = 50). Those who had at least a PR to induction therapy, a human leukocyte antigen (HLA)-identical sibling donor, and were younger than 56 years received an allogeneic BMT (n = 11).There was no statistically significant difference in OS between the autologous and allogeneic transplantation groups; however, there was a trend toward improved EFS in the allogeneic BMT group (P = .078).
Autologous versus Allogeneic SCT
Seiden et al. performed a prospective study in MM patients of autologous monoclonal antibody-purged BMT (n = 36) or a T-cell depleted allogeneic BMT (n = 22) if an HLA-compatible sibling donor was available [19] [20] [21] . Eighty-one percent of autologous BMT patients were alive at the median followup of 27 months versus 64% of allogeneic BMT patients alive at a median follow-up of 20 months. Thirty-nine percent of autologous patients were alive and FFP 18 months post-BMT versus 33% of allogeneic patients alive and FFP 30 months post-BMT.
Bjorkstrand et al. retrospectively compared 189 allogeneic BMT patients with HLAidentical sibling donors to 189 autologous PBSCT patients in a matched case-control study using European Group for Blood and Marrow Transplantation (EBMT) Registry data [22] . Median OS was significantly longer in the autologous PBSCT group compared with the allogeneic BMT group (34 versus 18 months; P = .001). Median PFS was also longer in the autologous PBSCT group (18 versus 10 months).
Reynolds et al. performed a retrospective single-center comparison of 35 autologous PBSCT patients with 21 historical allogeneic ASBMT BMT (n = 6) or PBSCT (n = 15) patients with related donors; both autologous and allogeneic SCT patients were given an identical conditioning regimen: busulfan plus Cy plus TBI (900 cGy) [24] . The Kaplan-Meier probability of disease progression was 11% in the allogeneic group and 64% in the autologous group (p < .001). Two-year PFS (60% versus 30%; P = .19), 2-year OS (60% versus 42%; P = .39), and TRM were higher in the allogeneic group but were not statistically significantly different.
Couban et al. retrospectively compared a cohort of 40 autologous PBSCT and 24 allogeneic BMT or PBSCT patients transplanted for MM at a single center [25] . Three-year PFS was not statistically significantly different between autologous (17%; 95% CI, 0-36.6) and allogeneic (22%; 95% CI, 4-39.6) transplants. Three-year OS was significantly higher in autologous (74%; 95% CI, 52.4-95.6) versus allogeneic (32%; 95% CI, 12.4-51.6) transplant patients.
Autologous SCT
Several studies have demonstrated the feasibility, safety, and efficacy of PBSCT and/or BMT with MEL-based conditioning regimens in previously untreated, newly diagnosed MM patients [26] [27] [28] [29] , as salvage therapy for relapsed or refractory disease [30] [31] [32] [33] [34] [35] [36] , and in MM patient populations with mixed disease responses to prior therapy [37] [38] [39] [40] [41] [42] . Three studies demonstrated the safety and efficacy of autologous transplantation: 1 study in 17 MM patients aged older than 65 years [43] [44] [45] [46] . Four studies have been completed for patients in renal failure [47] [48] [49] .
Autologous PBSCT versus BMT
Raje et al. compared two sequential phase II studies: the first of patients receiving autologous BMT (n = 26), the second of individuals treated with autologous PBSCT (n = 37) [50] . PBSCT patients recovered platelets significantly faster than BMT patients; however, there were no significant differences with regard to neutrophil engraftment, OS, or PFS.
Harousseau et al. retrospectively compared 81 autologous BMT patients with 51 autologous PBSCT patients from 18 French centers who were treated during a 7-year period [51] . There was no significant difference between the PBSCT and BMT groups regarding CR rate, overall response rate, OS, EFS, or relapse-free survival (RFS). PBSCT patients had a significantly shorter time to neutrophil engraftment but no significant difference in platelet recovery compared with BMT patients. Table 8 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles, some of which are detailed in this section.
Autologous CD34 + Selected versus Unselected PBSCT
Stewart et al. performed a multicenter randomized phase III trial of CD34 + selected (n = 93) versus unselected PBSCT (n = 97) for the treatment of MM [52, 53] . There was no difference in the median PFS ( Figure 5 ) or median OS between the CD34 + selected versus unselected treatment arms.
Several feasibility studies of CD34 + selection of PBSC harvests demonstrated its ability to reduce the tumor burden in the products without adversely affecting engraftment kinetics [54] [55] [56] [57] [58] [59] , and one study demonstrated the feasibility of performing CD34 + selection from multiple cycles of stem cell mobilization and collection [60] .
Two studies compared CD34 + selected versus unselected autologous PBSCT patients in prospective, non-randomized clinical trials and found no significant differences in neutrophil or platelet recovery between the 2 groups [61, 62] . One study demonstrated that all patients who received a high cell dose had significantly faster neutrophil engraftment and platelet recovery than those who received a low cell dose [63] .
One study compared single versus tandem CD34 + selected PBSCT in a non-randomized prospective trial [64] and found no difference in platelet or neutrophil recovery in single or tandem SCT when comparing CD34 + selected versus unselected PBSCT. One case-control study showed a significantly longer time to neutrophil and platelet recoveries in CD34 + selected PBSCT patients but no difference in PFS or OS [65] .
Autologous Purged versus Unpurged SCT
Three small studies of fewer than 15 patients each reported the feasibility of different pre-transplant purging techniques, including marrow purged ex vivo with 4-hydroperodxycyclophosphamide [66] ; ex vivo immunomagnetic depletion of PBSCT with CD34
+ selected products to purge B-lin cells [67] ; and CD34 + selected products followed by CD19 depletion [66] .
Barbui et al. randomized 60 newly diagnosed symptomatic MM patients to receive either unmanipulated (n = 31) or purged (n = 29) tan- 
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Blood and Marrow TRANSPLANTATION dem PBSCT [69] . There was no difference in the time to neutrophil or platelet recovery, discharge from hospital, or transfusion requirements between the purged and unpurged PBSCTs. At a median follow-up of 23 months, the 3-year EFS rate was 72% in the purged and 40% in the unpurged PBSCT group (P = .05). The 3-year OS rate was 83% for the purged and 83% for the unpurged PBSCT groups. Table 9 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles, some of which are detailed in this section.
Autologous Tandem versus Single SCT
In Barlogie et al. [5] additional patients were accrued in the tandem transplantation regimen and follow-up of the original patients was updated [70] . By intent-to-treat, 5-year OS and EFS rates for tandem transplant patients were 58% and 42%, respectively. Vesole et al. compared patients with advanced and refractory MM who received MEL with no stem cell rescue (MEL100) versus MEL plus TBI or thiotepa plus TBI and autologous BMT (MEL140) versus MEL with autologous BM plus PBSCT as a tandem transplantation (MEL200) [71] . A multivariate regression analysis of favorable factors for EFS found that low B2M, MEL200, primary unresponsive disease, and age 50 years or younger were statistically significant. B2M, MEL200, ≤12 months from diagnosis, and age 50 years or younger were statistically significant predictors of prolonged OS.
Siegel et al. compared tandem transplantation in a sample of 49 patients with advanced stage MM aged 65 years or older to pair-mates younger than 65 years matched on 5 prognostic factors [72] . Median durations of EFS and OS and TRM were not significantly different between the younger and older groups. Table 10 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the 
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Blood and Marrow TRANSPLANTATION reviewed articles. Seven studies have described the feasibility and efficacy of novel conditioning regimens [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] ; 5 studies have retrospectively compared SCT regimens for single transplantations [85] [86] [87] [88] [89] [90] [91] , and 1 study for tandem transplantation [92] .
Autologous High-Dose Sequential Therapy
Palumbo et al. investigated an intensified regimen in 68 patients newly diagnosed with MM treated with dexamethasone, adriamycin, and vincristine (DAV) ×3 cycles for induction therapy [93, 94] . By intent-to-treat, CR was induced in 27% of patients; CR plus PR was induced in 85%. TRM was 3%; median EFS was 35.6 months. Table 11 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles.
Prognostic Factors for OS, EFS, CR Rate, and Favorable Engraftment in Patients Treated with Autologous SCT
Other observations included the following: plasma cell labeling index was significantly higher in patients with abnormal cytogenetics [108, 118] ; prolonged prior therapy with alkylating agents (more than 1 prior cycle of chemotherapy before SC mobilization) was associated with developing myelodysplastic syndrome (MDS) posttransplantation [119] ; elevated plasma cell light chain ratio (LCR) in the first 60 days post-SCT most likely indicated residual tumor and not early relapse, however, an elevated LCR >90 days post-SCT significantly correlated with disease progression [120] ; failure to achieve CR (as measured by electrophoresis and immunofixation) after SCT was independently predicted by prior therapy with 2 or more chemotherapy regimens, nonresponsive disease at time of SCT, and TBI-containing conditioning regimen [121] .
Syngeneic SCT
Only two small studies of patients treated with BMT from syngeneic donors were available for review. One, a retrospective casematched analysis, compared MM patients treated with syngeneic BMT to autologous SCT and allogeneic SCT patients. [122] A second described patients with MM given salvage therapy with a BMT from syngeneic donors [123] . No treatment recommendations were made due to insufficient evidence. are available Table 12 summarizes the evaluation of the quality and strength of the evidence, patient characteristics, and outcome measures for the reviewed articles.
Allogeneic SCT
Prognostic Factors for PFS, OS, and EFS in Patients Treated with Allogeneic SCT
There is no evidence or insufficient evidence to make recommendations on the fol- [4, 71, 97, 98] Low ␤-2 microglobulin [104] Low C-reactive protein [97, 99] Immunoglobulin G isotype [100] High glomerular filtration rate [105] Early absolute lymphocyte count recovery [106] No deletion of chromosome 13q14 [107] Normal cytogenetics Independent clinical indicators of prolonged OS [17, 97, 98, [101] [102] [103] [104] Disease status at time of SCT (in CR or with chemotherapy-responsive disease) [15] [16] [17] SCT as de novo therapy (vs. salvage) [8, 96] Achievement of CR post-SCT [22, 25] Autologous SCT (vs. allogeneic) [102] Melphalan-containing conditioning regimen [102] Male gender [102] Stage I disease at diagnosis [12] Younger age Clinical and laboratory indicators that are not significant predictors of OS or EFS [108] Number of reinfused plasma cells (EFS) [109] Light chain associated amyloidosis (OS/EFS) [110] Magnetic resonance imaging pattern 1 mo before and after SCT (OS) Clinical and laboratory indicators in tandem PBSCT Higher CR rate [111] Low ␤-2 microglobulin [111] Low C-reactive protein [111] No chromosome 13 abnormalities [111] Less than 1 y of prior chemotherapy Prolonged OS and EFS [70, 72, [112] [113] [114] Absence of chromosomal abnormalities [70, 72, [112] [113] [114] Low ␤-2 microglobulin [113] Low C-reactive protein [113] Attainment of CR [113] Two PBSCTs given within a 6-month period [112, 114] Shorter duration of chemotherapy before first PBSCT Clinical and laboratory indicators for favorable/rapid engraftment after SCT Platelet engraftment [115] Cy + G-CSF (vs. G-CSF alone) as SC mobilization regimen [115] No prior oral MEL exposure Neutrophil and platelet engraftment [116] No prior MEL exposure [116] >2 × 10 6 CD34 + cells/kg infused [117] Duration of prior chemotherapy [117] Number of CD34 + cells infused [117] ≤24 months of prior chemotherapy needs ≥2.0 × 10 6 CD34 + cells/kg [117] >24 months of prior chemotherapy needs 5.0 × 10 6 CD34 + cells/kg ASBMT lowing issues related to allogeneic SCT (Table 13 ):
• Allogeneic SCT nonmyeloablative conditioning regimen [124] [125] [126] [127] [128] [129] .
• Allogeneic PBSCT versus BMT [131] .
• Preferred allogeneic SCT myeloablative conditioning regimen [132] [133] .
• Allogeneic high-dose sequential regimen.
Therapy Post-SCT
Due to insufficient evidence, no recommendation was made of a preferred maintenance therapy posttransplantation, including maintenance interferon, donor lymphocyte infusion and second transplant for relapse. The question was recommended for comparative study.
Economic/Cost-Effectiveness Studies
Several studies have examined the costeffectiveness of stem cell transplantation with varying results, depending on the patient population studied, the range of direct and/or indirect costs included, and the stated endpoints of the analysis. These are detailed in the unabridged version of this review.
Response Criteria (Methods to Detect Minimum Residual Disease)
Various techniques to measure biochemical or molecular tumor markers have been examined for their ability to detect minimum residual disease in apheresis products, BM harvests, or in MM patients pre-and posttransplantation and to predict prognosis. There is not sufficient evidence, however, to recommend a preferred method to detect minimum residual disease.
Ongoing Studies
Several studies have been published in abstract form only, have recently been completed, or are currently accruing patients that address critical issues that will affect treatment recommendations based on the evidence available at the time of this review. The final analyses of mature data from these studies will provide additional evidence that may change and/or add to the conclusions and recommendations of the authors.
Limitations of this Evidence-Based Literature Review
There are limitations to any evidencebased review of the published literature. The criteria for this review included only data from peer-reviewed manuscripts published since 1980. Unpublished data and data published only in abstract form were excluded. Another limitation is the review' s reliance on published data rather than individual patient data. Although it was not the objective of this review to perform a meta-analysis of individual patient data, such an analysis is warranted in the future to further clarify the results of studies and address questions that remain unanswered.
Discussion
Several studies have been published in abstract form only, were recently completed, or are currently accruing patients but address critical issues that will affect the treatment recommendations made above [137] [138] [139] [140] [141] .
The panel recommends studies of postresponse therapy to improve the quality of the response and extend survival as the most important area of needed research.
In addition to the topics covered, we reviewed the evidence for PBSC mobilization regimens, and timing of PBSC collections for SCT and vaccine therapy post-autologous SCT. The panel concluded that there was not adequate evidence to make meaningful recommendations in these areas. The panel noted that although expert opinion has set an upper age limit of 70 years for autologous SCT, the decision for transplantation in the elderly population should be made on a case-by-case basis.
The authors recommend methodology standardization, including study design, analytical tests, and response criteria. Multicenter randomized phase III comparative trials with large enrollments and high statistical power are required in the United States to advance the field more constructively than single institution phase II trials with one treatment arm. We advocate prompt reporting of mature data in full manuscript format.
The treatment recommendations of this panel are based on the results of well-planned, scientifically sound, peer-reviewed clinical trials. All of today' s current therapy for cancer is the result of the randomized clinical trial process. It is currently estimated that less than 5% of adults eligible to participate in cancer clinical trials actually enroll in a trial. The authors acknowledge the importance of third Statistically significant independent indicators of prolonged PFS [126] Chemotherapy-sensitive disease at time of SCT [127] <Stage III disease Statistically significant independent indicators of prolonged OS [124, 134] Achievement of CR post-SCT [124] Grade I acute GVHD [134] <Grade III acute GVHD [135] Chemotherapy-sensitive disease at time of SCT [135] Low B-2 microglobulin (<2.5 g/L) [135] Less than 1 y between diagnosis and SCT [128] Fewer cycles of chemotherapy prior to allogeneic SCT Statistically significant independent indicators of prolonged EFS [131] Chemotherapy-sensitive disease at time of SCT [135] No prior autologous SCT [135] Creatinine clearance > 100 mL/min | 13 
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